Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 719

1.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Sep 3. doi: 10.1038/s41422-019-0224-x. [Epub ahead of print]

PMID:
31481761
2.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol. 2019 Aug 13. pii: mdz224. doi: 10.1093/annonc/mdz224. [Epub ahead of print] No abstract available.

PMID:
31408090
3.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.

Eur J Cancer. 2019 Aug 7;119:1-10. doi: 10.1016/j.ejca.2019.07.001. [Epub ahead of print]

PMID:
31400634
4.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, Tagliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6.

PMID:
31288208
5.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
6.

Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop.

Lorigan P, Eggermont AMM.

Ann Oncol. 2019 Jul 1;30(7):1038-1040. doi: 10.1093/annonc/mdz182. No abstract available.

PMID:
31218362
7.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
8.

Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.

Moya-Plana A, Herrera Gómez RG, Rossoni C, Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot F, Eggermont AMM, Robert C.

Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7.

PMID:
31172258
9.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Jun;114:117-127. doi: 10.1016/j.ejca.2018.12.036. Epub 2019 May 13.

PMID:
31096150
10.

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F.

J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5.

11.

Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma.

Eggermont A, Suciu S, Kicinski M.

N Engl J Med. 2019 Apr 4;380(14):1374-1376. doi: 10.1056/NEJMc1902228. No abstract available.

PMID:
30943345
12.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
13.

Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer.

Ringborg U, Celis JE, Baumann M, Eggermont A, Wild CP, Berns A.

Mol Oncol. 2019 Mar;13(3):497-501. doi: 10.1002/1878-0261.12464. Epub 2019 Feb 27. No abstract available.

14.

Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

Eggermont AMM, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Calvo F.

Mol Oncol. 2019 Mar;13(3):521-527. doi: 10.1002/1878-0261.12447. Epub 2019 Feb 2. Review.

15.

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.

Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F.

Nat Commun. 2018 Nov 30;9(1):5097. doi: 10.1038/s41467-018-07603-1.

16.

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.

Hirsch L, Zitvogel L, Eggermont A, Marabelle A.

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

PMID:
30413824
17.

Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.

Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C.

Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29.

PMID:
30374200
18.

Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, Sprangers MA, Groenvold M, Velikova G, Flechtner HH, Brandberg Y; EORTC Melanoma Group and EORTC Quality of Life Group.

Eur J Cancer. 2018 Nov;104:169-181. doi: 10.1016/j.ejca.2018.09.005. Epub 2018 Oct 22.

PMID:
30359910
19.

Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes.

Verver D, van Klaveren D, Franke V, van Akkooi ACJ, Rutkowski P, Keilholz U, Eggermont AMM, Nijsten T, Grünhagen DJ, Verhoef C.

Br J Surg. 2019 Feb;106(3):217-225. doi: 10.1002/bjs.10995. Epub 2018 Oct 11.

20.

European Academy of Cancer Sciences - position paper.

Adami HO, Berns A, Celis JE, de Vries E, Eggermont A, Harris A, Zur Hausen H, Pelicci PG, Ringborg U.

Mol Oncol. 2018 Nov;12(11):1829-1837. doi: 10.1002/1878-0261.12379. Epub 2018 Sep 21.

21.

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Calvo F, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Eggermont A.

Eur J Cancer. 2018 Nov;103:155-159. doi: 10.1016/j.ejca.2018.08.023. Epub 2018 Sep 18.

PMID:
30241002
22.

Combination Immunotherapy Development in Melanoma.

Eggermont AMM, Crittenden M, Wargo J.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:197-207. doi: 10.1200/EDBK_201131. Review.

PMID:
30231333
23.

A roadmap for restoring trust in Big Data.

Lawler M, Morris AD, Sullivan R, Birney E, Middleton A, Makaroff L, Knoppers BM, Horgan D, Eggermont A.

Lancet Oncol. 2018 Aug;19(8):1014-1015. doi: 10.1016/S1470-2045(18)30425-X. No abstract available.

PMID:
30102210
24.

Adjuvant Pembrolizumab in Resected Stage III Melanoma.

Eggermont AMM, Robert C, Suciu S.

N Engl J Med. 2018 Aug 9;379(6):593-595. doi: 10.1056/NEJMc1807505. No abstract available.

PMID:
30089063
25.

Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.

Jacquelot N, Zitvogel L, Eggermont AM.

Nat Commun. 2018 Jul 26;9(1):2922. doi: 10.1038/s41467-018-05048-0. No abstract available.

26.

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.

Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I.

Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.

27.

The new era of adjuvant therapies for melanoma.

Eggermont AMM, Robert C, Ribas A.

Nat Rev Clin Oncol. 2018 Sep;15(9):535-536. doi: 10.1038/s41571-018-0048-5. No abstract available.

28.

Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ.

Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13.

PMID:
29660597
29.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

30.

European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of Excellence.

Ringborg U, Celis J, Eggermont A, Berns A.

Eur J Cancer. 2018 Apr;93:138-139. doi: 10.1016/j.ejca.2018.01.003. Epub 2018 Feb 14. No abstract available.

PMID:
29454744
31.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.

Testori AA, Suciu S, van Akkooi ACJ, Suppa M, Eggermont AMM, de Vries E, Joosse A; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group.

Melanoma Res. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433.

PMID:
29432281
32.

Neoadjuvant therapy in melanoma: the next step?

Ascierto PA, Eggermont AMM.

Lancet Oncol. 2018 Feb;19(2):151-153. doi: 10.1016/S1470-2045(18)30016-0. Epub 2018 Jan 18. No abstract available.

PMID:
29361473
33.

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S.

Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12.

34.

Development and evaluation of an isolated limb infusion model for investigation of drug delivery kinetics to solid tumors by thermosensitive liposomes and hyperthermia.

Lokerse WJM, Eggermont AMM, Grüll H, Koning GA.

J Control Release. 2018 Jan 28;270:282-289. doi: 10.1016/j.jconrel.2017.12.012. Epub 2017 Dec 18.

PMID:
29269141
35.

Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria.

Voit CA, van Akkooi ACJ, Catalano O, Eggermont AMM.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):661-662. doi: 10.1245/s10434-017-6230-7. Epub 2017 Nov 20. No abstract available.

PMID:
29159735
36.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

37.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
38.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

39.

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Eggermont AMM, Dummer R.

Eur J Cancer. 2017 Nov;86:101-105. doi: 10.1016/j.ejca.2017.09.014. Epub 2017 Sep 29.

PMID:
28968566
40.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

41.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
42.

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L.

Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017. Review.

43.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

44.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
45.

Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45].

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2017 Sep;82:247. doi: 10.1016/j.ejca.2017.06.001. Epub 2017 Jun 26. No abstract available.

PMID:
28662904
46.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
47.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

48.

Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer.

Lokerse WJM, Bolkestein M, Dalm SU, Eggermont AMM, de Jong M, Grüll H, Koning GA.

J Control Release. 2017 Jul 28;258:34-42. doi: 10.1016/j.jconrel.2017.05.005. Epub 2017 May 4.

PMID:
28479096
49.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108.

PMID:
28368458
50.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

Supplemental Content

Loading ...
Support Center